Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Samarthakrupa Lifesciences is an Indian biotechnology company specializing in autologous regenerative cell therapies. The company's lead clinical program, IndiSK Regenerative Cell Therapy, utilizes autologous cultured disc chondrocytes embedded in autologous platelet-rich fibrin (PRF) to treat intervertebral disc degeneration and associated back pain. Samarthakrupa Lifesciences operates a Good Manufacturing Practice (GMP)-compliant therapeutic cell culture facility in collaboration with BKL Walawalkar Hospital in Sawarde, Maharashtra. Supported by India's Biotechnology Industry Research Assistance Council (BIRAC), the company is actively advancing its cell therapy pipeline through Phase 1 clinical trials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Samarthakrupa Lifesciences.